Objectives. This study was undertaken to determine whether lipoprotein(a) [Lp(a)] is an independent risk factor for ischemic heart disease (IHD) and to establish the relation of Lp(a) to the other lipid fractions.
Several studies have shown that elevated lipoprotein(a) [Lp(a)] concentrations are associated with ischemic heart disease (IHD) (1) (2) (3) (4) (5) (6) , restenosis after percutaneous transluminal coronary angioplasty (PTCA) (7, 8) , coronary artery disease progression (9, 10) , cerebrovascular disease (11) (12) (13) and intermittent claudication (14 -16) . Most of the currently available evidence on Lp(a) as risk factor for IHD is derived from case-control studies (1, 2, 5, 17, 18 ) and a few prospective population-based studies: one from Iceland reported by Sigurdsson et al. (3) , the Göttingen Risk Incidence and Prevalence Study (GRIPS) (19) and the report of Bostom et al. (20) in a group of men from the Framingham cohort. However, the potential relation between Lp(a) and IHD has been questioned by many case-control studies (2, 17, 21, 22) and the cross-sectional Finland Cardiovascular Risk (FINRISK) Haemostasis Study (23) , all of which failed to identify a similar relation. Thus, there is some controversy as to the role of Lp(a) as an independent risk factor for IHD. It is possible that Lp(a) may contribute to IHD risk through synergistic mechanisms with low density lipoprotein (LDL) cholesterol, as suggested by a study of familial hypercholesterolemia (24) and the GRIPS trial (19) . The present study sought to examine whether Lp(a) is an independent risk factor for, and may contribute to the effect of other lipid fractions in IHD, in 2,156 French Canadian men prospectively followed up from 1985 until 1990.
Methods
Patients, risk factor evaluations and follow-up. The study was approved by the ethics committee of the Faculty of Medicine, Laval University, Ste-Foy, Quebec, Canada. The random selection of participants and screening methods have been previously described (25) . Briefly, 4,637 men 35 to 64 years old in 1973 and living in Quebec City suburbs participated in the Quebec Cardiovascular Study. Among these 4,637 men, 252 were excluded because they had coronary or vascular disease before entry into the study. The initial screening was conducted from December 1973 to July 1974. The cohort was evaluated approximately every 5 years. In 1985, cohort participants were invited to participate in an evaluation that included a complete questionnaire on cardiovascular diseases, diabetes, smoking and medication, blood pressure, height and weight measurements, an electrocardiogram as well as a fasting plasma lipid profile. Rest blood pressure measurements were performed after a 5-min rest in a sitting position using phases 1 and 5 of the Korotkoff sounds for systolic and diastolic blood pressure, respectively. The mean of two blood pressure measurements taken 5 min apart was used in the analyses. Diabetes was considered only if men were treated with hypoglycemic agents. Smoking status was defined as follows: 1) nonsmokers (never smoked); 2) ex-smokers (those who discontinued their habit at least 1 year before evaluation); 3) pipe or cigar smokers, or both; 4) smokers consuming 1 to 20 cigarettes/day; and 5) smokers of Ն21 cigarettes/day. In 1985, fasting blood samples could be obtained in 2,261 of the 3,747 living men without IHD. Among the 1,486 men who did not have lipid determinations, 1,025 (69%) refused the evaluation or were evaluated at their home clinic; 356 (24%) were excluded because they were not in a fasting state; and 105 (7%) could not be located in 1985. Nevertheless, the age distribution of the 2,261 men included in the study was representative of the original cohort, and the event rate was similar to that found in men who had remained event free until 1985. In 1990, all men were contacted by mail and invited to answer a short standardized questionnaire on smoking habits, cardiovascular diseases, medication and diabetes. Telephone calls were made to participants who did not answer a second letter and, if unsuccessful, to a close family member. At the end of the follow-up period (September 1, 1990), mortality and morbidity data had been obtained for 99% and 96% of the participants, respectively.
Clinical evaluation of IHD. The diagnosis of IHD events was based on typical description of symptoms, ECG findings and biochemical analyses or autopsy results. Angina was diagnosed solely on the basis of typical retrosternal squeezing or heaviness discomfort Ͻ5 min in duration, brought on by exertion and relieved by rest or administration of nitroglycerin, or both, and was always confirmed by a cardiologist of the study group. Coronary insufficiency was considered when typical chest pain was prolonged from 5 to 15 min and was accompanied by ECG changes. Myocardial infarction (MI) was diagnosed according to ECG criteria 1.1 of the Minnesota code or in the presence of two of the following three criteria: prolonged typical chest pain, ischemic ECG changes or creatine kinase elevation twice above the upper normal limit. MI was considered fatal when death occurred within 28 days of the initial event. Coronary deaths were diagnosed according to the autopsy findings or by exclusion of other causes. Diagnoses were completed from hospital files by trained health professionals and were confirmed by a cardiologist (G.R.D.) unaware of the risk factor profile of the participants. Informed consent for review of hospital files was obtained from the participants or from the hospital authorities for participants who had died. For the participants who died outside the hospital, the cause of death was obtained from the Provincial Death Registry, and a cardiologist from the study interviewed a member of the immediate family as to the circumstances of death.
Lipoprotein determinations. All lipoprotein determinations were made after an overnight fast. Laboratory determinations were standardized using control sera obtained from the Centers for Disease Control and Prevention (Atlanta, Georgia). Blood samples were obtained by venipuncture into EDTA-containing tubes. Blood samples were centrifuged at low speed to obtain plasma, and aliquots were stored at Ϫ80°C. Total cholesterol was determined from fresh plasma samples after extraction in isopropanol using an Auto-Analyzer II (Technicon Instruments Inc.). High density lipoprotein (HDL) cholesterol levels were obtained by heparin-manganese precipitation (26 -28) . Except for patients with dysbetalipoproteinemia or those in whom triglyceride levels were Ͼ4.5 mmol/liter, LDL levels were calculated as described by Friedewald et al. (29) . The electroimmunoassay of Laurell (30) was used to quantitate plasma apolipoprotein B levels. Plasma Lp(a) concentrations were measured in 1992 from samples frozen in 1985 that were thawed to 4°C. Lp(a) concentrations were measured by enzyme-linked immunosorbent assay (ELISA) using kits obtained from Biopool (Umeå, Sweden).
Statistical analyses. Follow-up duration in person-years was calculated according to the participation of each subject from the 1985 evaluation until the last contact or first IHD event. Differences in mean values for risk factors were tested by analysis of variance, and differences in smoking and diabetes rates were tested by chi-square analysis.
Adjusted risk ratios of IHD were calculated as the adjusted rates for tertiles 2 and 3, divided by the corresponding rate for tertile 1 using a Cox proportional hazards model (31) . For smokers and ex-smokers, the relative risk was determined by dividing their rates of IHD by the rate of those who never smoked. In these analyses, two models were used. In both instances, age, systolic blood pressure, smoking status and Lp(a) levels were included. In model 1, total cholesterol was also entered. In model 2, total cholesterol was replaced by LDL and HDL cholesterol. A stepwise discriminant analysis was also performed for each model to further evaluate the effect of Lp(a) on IHD. These analyses were repeated in a subset of men in whom angina and coronary insufficiency as a first event were excluded.
Finally, to evaluate any synergy between Lp(a) and significant lipid risk factors, subjects were classified into groups using lipid value tertiles and either high (Ն30 mg/dl) or low (Ͻ30 mg/dl) Lp(a) levels. Each of the first tertiles of lipid risk factor Abbreviations and Acronyms ECG ϭ electrocardiogram, electrocardiographic GRIPS ϭ Göttingen Risk Incidence and Prevalence Study HDL ϭ high density lipoprotein IHD ϭ ischemic heart disease LDL ϭ low density lipoprotein Lp(a) ϭ lipoprotein(a) MI ϭ myocardial infarction NCEP ϭ National Cholesterol Education Program PTCA ϭ percutaneous transluminal coronary angioplasty distribution combined with low (Ͻ30 mg/dl) Lp(a) levels was assigned a relative risk of 1. Subjects in the other groups [first tertile and high Lp(a); second tertile and low Lp(a); second tertile and high Lp(a); third tertile and low Lp(a); third tertile and high Lp(a)] were compared with the reference group using a Cox proportional hazards model to evaluate potential interactions between Lp(a) and other risk factors.
Results
During the follow-up period, there were 116 first IHD events: 51 men had an MI; 41 experienced angina; 9 had coronary insufficiency; and 15 died. Baseline characteristics of men with and without IHD are summarized in Table 1 . Fewer than 5% of men in either group were using hypolipidemic drugs in 1985. Men with IHD were older, smoked more, had a higher systolic blood pressure and prevalence of diabetes as well as elevated total cholesterol, LDL cholesterol, apoprotein B and Lp(a) levels and low HDL-cholesterol levels. Figure 1 shows the distribution of Lp(a) levels in men with and without IHD.
Lp(a) levels correlated positively with total cholesterol, LDL cholesterol and apoprotein B (Table 2) . In both models, age, systolic blood pressure and smoking were found to correlate significantly with IHD. However, Lp(a) was never found to be an independent risk factor for IHD (Table 3) . In model 1, the highest tertile of total cholesterol was associated with an increased IHD risk. In model 2, cholesterol within lipoprotein fractions was also related to IHD. LDL cholesterol in the two highest tertiles was associated with an increased IHD risk, whereas the highest HDL cholesterol tertile had a protective effect. Stepwise discriminant analyses of each model yielded essentially similar results (Table 4 ). In view of the distribution of Lp(a) values in the cohort, a logarithmic transformation of Lp(a) data was performed to evaluate its potential as a risk factor. Cutoff values for high and low Lp(a) (25, 30, 35 and 75 mg/dl) were also used to treat it as a dichotomic variable in proportional hazards and stepwise analyses. None of these approaches could reveal a significant impact of Lp(a) on IHD. Finally, the multivariate analyses (Cox proportional hazards and stepwise discriminant) were done using data from patients who experienced MI or coronary death. These analyses yielded similar results: age, systolic blood pressure and cholesterol levels were significant and independent risk factors, whereas Lp(a) was not. Table 5 examines the synergy between known lipid risk factors and Lp(a). As shown in Table 3 , the last tertile of the cholesterol distribution was associated with an increased risk of IHD. However, this risk was further increased by the presence of Lp(a) concentrations Ն30 mg/dl. In Table 3 , the second tertile of the LDL cholesterol distribution was associated with an increased risk of IHD. The data in Table 5 show that this risk was associated with the presence of increased Lp(a) levels. It also appeared that the significant risk found in *p Ͻ 0.05. †Since low density lipoprotein cholesterol (LDL-C) levels were calculated: n ϭ 114 with and n ϭ 1,990 without ischemic heart disease (IHD). Data presented are mean value Ϯ SD or percent of patients. Apo B ϭ apoprotein B; BP ϭ blood pressure; HDL-C ϭ high density lipoprotein cholesterol; Lp(a) ϭ lipoprotein(a); Total-C ϭ total cholesterol. the third tertile of the LDL cholesterol distribution is not increased by the presence of elevated Lp(a). For HDL cholesterol, the protective effect against IHD associated with the third tertile of the distribution (Table 3 ) was lost when there was a simultaneous elevation in Lp(a) ( Table 5 ). There was a significant increase in risk of IHD found in the second tertile of the apoprotein B distribution if there was a concomitant elevation of Lp(a) levels. However, the last tertile of the apoprotein B distribution was associated with an increased risk of IHD, and it appeared that the presence of elevated Lp(a) further increased this risk (Table 5) . For all these lipid risk factors, the presence of Lp(a) levels Ն30 mg/dl in the first tertile of the distribution was never associated with a significant increase in risk of IHD.
Discussion
As expected, age, systolic blood pressure, smoking and total, LDL and HDL cholesterol were significant independent risk factors for a first IHD event in this cohort. The present study indicated that elevated Lp(a) is not an independent risk factor for a first IHD event in men, a finding that is also supported by logarithmic and dichotomic manipulation of Lp(a) data. However, there appears to be an interaction between elevated Lp(a) concentration and total, LDL and HDL cholesterol and apoprotein B levels.
Lp(a) and IHD. The differences between our study and others regarding the contribution of Lp(a) as an independent risk factor for IHD may most likely be the result of different patients studied, experimental designs and technical approaches to the determination of Lp(a) levels. We used a population-based prospective model in a primary prevention setting, whereas most studies have been case-control or retrospective studies, with limited numbers of subjects. There were also differences in end points. Most studies considered only MI and coronary death as events, whereas we also included both typical effort angina and coronary insufficiency with documented ECG ischemic changes along with MI and IHD death. Nevertheless, when only MI and IHD death were considered, Lp(a) was not a significant predictor in the present sample. , age, systolic blood pressure (BP) and smoking status were included in both models; in model 1, total cholesterol (Total-C) levels were also included; in model 2, total cholesterol was replaced by low density lipoprotein (LDL-C) and high density lipoprotein cholesterol (HDL-C). CI ϭ confidence interval; cig ϭ cigarettes; RR ϭ risk ratio. †p Ͻ 0.05 versus first tertile of risk factor distribution.
Other studies have also failed to show a relation between Lp(a) and IHD. For instance, a Finnish population-based prospective case-control study (22) could not find that Lp(a) was a risk factor for MI. A nested case-control study of men from the Helsinki Heart Study (2), also using MI as an end point, did not find a relation between Lp(a) and MI. In contrast, there are three population-based, prospective studies showing a relation between Lp(a) and MI. The first (3), carried out in Iceland, studied 1,332 men, 104 of whom had a fatal or nonfatal MI (3) . In that study, the event rate was roughly threefold that found in our patients or in the Framingham population (32) , and cigarette smoking was not a predictor of MI, which is at odds with most published reports. The second study (GRIPS [19] ) found a significant relation between fatal and nonfatal MI and Lp(a). Men in the GRIPS trial, despite their younger age, had relatively higher mean total and LDL cholesterol levels than men in the present study. In the GRIPS trial, LDL cholesterol was found to be the most important predictor of MI, whereas elevated blood pressure and smoking were not predictors of MI in multivariate models. This was not the case for the present study, where age was the most important risk factor, followed by systolic blood pressure, smoking and LDL cholesterol. Finally, a recent study by the Framingham group (20) in men 20 to 55 years old followed up for 15 years used end points similar to ours. Once again, there are striking differences between the reports. As would be expected, when the age differences are considered, our event rate is much higher than that found by Bostom et al. (20) . Furthermore, multivariate analyses that showed Lp(a) to be an independent risk factor were done using a model that dichotomized risk factors, such as total LDL and HDL cholesterol. These lipid values were dichomotized using lipid levels in accordance with the National Cholesterol Education Program (NCEP) (33) for men without IHD and with fewer than two risk factors. Because of evidence that shows that the relation between cholesterol and IHD risk is continuous (34) and a recently published clinical trial (35) of lipid lowering that shows that patients with so-called normal cholesterol levels benefit from lipid-lowering therapy, we elected to treat lipid values as continuous variables.
The GRIPS trial (19) also found an interaction between elevated LDL cholesterol, Lp(a) and MI. Lp(a) may thus have a predictive role for IHD in men with elevated LDL cholesterol levels. However, our study shows that these results may be attributable to a specific category of men with mildly elevated LDL cholesterol levels. Furthermore, our study suggests that elevated Lp(a) levels also enhance the risk associated with apoprotein B and total cholesterol. Although HDL particles may not be directly related to Lp(a), the beneficial effects associated with elevated HDL cholesterol levels were lost in the presence of elevated Lp(a) levels. Thus, despite significantly elevated levels in men with IHD, Lp(a) itself does not increase the risk of IHD risk, but it may modulate other risk factors in this male cohort prospectively followed up for 5 years. The results obtained with the second tertiles of LDL cholesterol and apoprotein B distribution may seem contradictory (Table 5 ). However, this contradiction could be a reflection of LDL particle size, which may be a better predictor of IHD than LDL cholesterol or apoprotein B levels (36) in the middle of their respective distributions.
Lp(a) measurement and storage. Also contributing to the controversy of Lp(a) as a risk factor are the different ways in which the samples are handled in different studies. There is a lack of standardization of the measurement methods and different assays (37) using various techniques (37, 38) . We selected an ELISA-type assay because it appears that Lp(a) measurements using such assays are not as affected by storage (39) as other assays. The question of storage has been raised as an explanation for the failure of studies to demonstrate an effect of Lp(a). A recent study by Kronenberg et al. (40) , also using an ELISA-based Lp(a) assay (but different from the kit that we used), suggested there was a decay in Lp(a) levels from samples stored for ϳ2 years at Ϫ80°C. Their data, based on 310 frozen samples, suggest that there might be greater decay in the samples with a higher content of lower molecular weight Lp(a). Such lower molecular weight Lp(a) is usually found in subjects with elevated Lp(a) concentrations. From these data they extrapolated that after 8 years of storage under these conditions, a difference of 9.6 mg/dl between groups would disappear. If this were true, the Lp(a) distribution in our cohort would not have been similar to that of other white populations (16) . Furthermore, the GRIPS trial was carried out with the same Lp(a) assay that we used and has shown that after 9 years of storage, Lp(a) levels are similar to those found in fresh samples (17) .
Lp(a) and atherosclerosis. A few mechanisms have been proposed for the putative role of Lp(a) in IHD. Its incorporation into plaque and high affinity binding to glycosaminoglycans and fibronectin suggest a direct atherogenic action in combination with elevated cholesterol (41) . Our study brings indirect confirmation of that hypothesis because Lp(a) could , age, systolic blood pressure (BP) and smoking status were included in both models; in model 1, total cholesterol (Total-C) levels were also included; in model 2, total cholesterol was replaced by low density lipoprotein (LDL-C) and high density lipoprotein cholesterol (HDL-C). Other abbreviations as in Table 3 .
not be found to be independent of other risk factors. Lp(a) has less resistance to oxidation than does the LDL particle (42, 43) and can be actively taken up by scavenger receptors, leading to the formation of foam cells (44) . Because of similarities of apoprotein(a) to domains of plasminogen, Lp(a) may impair fibrinolytic activity by competing with plasminogen for fibrin binding, by competing with tissue-type plasminogen activator for fibrin binding (45) (46) (47) or by direct binding to fibrin (41) . Further studies are required to demonstrate a synergistic mechanism between Lp(a) and other lipid fractions.
Conclusions. Our data show that in this population-based, prospective setting, Lp(a) is not an independent risk factor for IHD but appears to increase the risk associated with other risk factors. These findings have important clinical implications because they suggest that Lp(a) measurements should not be carried out in a primary prevention effort. It would appear that Lp(a) measurements might be useful in patients with IHD with other known risk factors, especially mildly elevated LDL cholesterol. Also noteworthy was the finding that the beneficial effects of elevated HDL cholesterol appeared to be lost in men with elevated Lp(a), which suggests that Lp(a) determinations may be useful in these men. The resistance of Lp(a) to lowering suggests that intervention on the other risk factor might be the appropriate therapeutic choice, a strategy that has already been proven effective in a tertiary prevention setting (48) . This hypothesis will need to be substantiated by appropriate lipid-lowering trials. Tables 1 and 3. 
